TG Therapeutics (TGTX) Short Interest Ratio & Short Volume → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free TGTX Stock Alerts $15.57 +0.13 (+0.84%) (As of 03/27/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability TG Therapeutics Short Interest DataCurrent Short Volume34,190,000 sharesPrevious Short Volume34,840,000 sharesChange Vs. Previous Month-1.87%Dollar Volume Sold Short$520.37 millionShort Interest Ratio / Days to Cover7.2Last Record DateMarch 15, 2024Outstanding Shares154,420,000 sharesFloat Size139,360,000 sharesShort Percent of Float24.53%Today's Trading Volume1,454,743 sharesAverage Trading Volume4,610,932 sharesToday's Volume Vs. Average32% Short Selling TG Therapeutics ? Sign up to receive the latest short interest report for TG Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatTGTX Short Interest Over TimeTGTX Days to Cover Over TimeTGTX Percentage of Float Shorted Over Time Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… TG Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/15/202434,190,000 shares $520.37 million -1.9%24.5%7.2 $15.22 2/29/202434,840,000 shares $599.94 million -2.6%25.0%6.7 $17.22 2/15/202435,780,000 shares $515.23 million +22.9%26.2%7.2 $14.40 1/31/202429,120,000 shares $472.91 million -5.2%21.4%5.6 $16.24 1/15/202430,700,000 shares $484.14 million -3.6%22.5%4.7 $15.77 12/31/202331,830,000 shares $543.66 million -12.8%23.2%5.2 $17.08 Get the Latest News and Ratings for TGTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for TG Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/15/202336,520,000 shares $674.89 million +1.7%26.6%6.3 $18.48 11/30/202335,920,000 shares $460.14 million -1.9%26.2%6.4 $12.81 11/15/202336,610,000 shares $412.59 million -1.1%26.7%6.8 $11.27 10/31/202337,020,000 shares $286.16 million -0.5%27.0%6.8 $7.73 10/15/202337,210,000 shares $248.93 million +14.5%27.2%7.2 $6.69 9/30/202332,510,000 shares $271.78 million +10.2%23.7%6.5 $8.36 9/15/202329,510,000 shares $299.23 million +5.5%21.5%6 $10.14 8/31/202327,970,000 shares $292.85 million +1.6%20.4%5.8 $10.47 8/15/202327,520,000 shares $317.31 million +19.2%20.1%5.8 $11.53 7/31/202323,080,000 shares $477.53 million +3.3%16.9%5 $20.69 7/15/202322,340,000 shares $493.71 million -1.1%16.5%5.7 $22.10 6/30/202322,580,000 shares $560.89 million +0.4%16.7%5.5 $24.84 6/15/202322,480,000 shares $595.27 million +0.2%16.6%5.4 $26.48 5/31/202322,430,000 shares $597.31 million +3.0%16.6%5.2 $26.63 5/15/202321,770,000 shares $678.14 million -15.0%16.1%5.1 $31.15 4/30/202325,610,000 shares $635.90 million -6.7%19.3%5.8 $24.83 4/15/202327,460,000 shares $557.99 million -3.4%20.7%6.6 $20.32 3/31/202328,420,000 shares $427.44 million +6.6%21.5%6.3 $15.04 3/15/202326,650,000 shares $394.15 million +2.6%20.1%4.7 $14.79 2/28/202325,970,000 shares $416.04 million +6.3%19.1%4.6 $16.02 2/15/202324,440,000 shares $472.67 million +4.2%18.1%4.5 $19.34 1/31/202323,450,000 shares $357.14 million +4.0%17.4%4.3 $15.23 1/15/202322,560,000 shares $307.49 million -3.3%16.7%4.4 $13.63 12/30/202223,340,000 shares $276.11 million +12.9%17.3%4.9 $11.83 12/15/202220,680,000 shares $178.26 million +6.9%15.3%7 $8.62 11/30/202219,350,000 shares $170.67 million -1.7%14.4%7.2 $8.82 11/15/202219,680,000 shares $173.38 million +2.3%14.6%7.6 $8.81 10/31/202219,230,000 shares $111.92 million -1.1%14.3%7.9 $5.82 10/15/202219,440,000 shares $105.56 million +5.8%14.5%7.6 $5.43 9/30/202218,380,000 shares $108.81 million +3.8%13.7%7 $5.92 9/15/202217,710,000 shares $129.28 million -3.1%13.2%6.6 $7.30 8/31/202218,270,000 shares $130.27 million -3.5%13.6%6.3 $7.13 8/15/202218,940,000 shares $159.10 million -7.1%14.1%5.9 $8.40 7/31/202220,380,000 shares $122.08 million -2.3%15.3%6.2 $5.99Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… TGTX Short Interest - Frequently Asked Questions What is TG Therapeutics' current short interest? Short interest is the volume of TG Therapeutics shares that have been sold short but have not yet been closed out or covered. As of March 15th, investors have sold 34,190,000 shares of TGTX short. 24.53% of TG Therapeutics' shares are currently sold short. Learn More on TG Therapeutics' current short interest. What is a good short interest ratio for TG Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. TGTX shares currently have a short interest ratio of 7.0. Learn More on TG Therapeutics's short interest ratio. Which institutional investors are shorting TG Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of TG Therapeutics: GTS Securities LLC, Wolverine Trading LLC, Parallax Volatility Advisers L.P., Citadel Advisors LLC, Cubist Systematic Strategies LLC, Capital Fund Management S.A., Hsbc Holdings PLC, IMC Chicago LLC, Concourse Financial Group Securities Inc., Simplex Trading LLC, and Cutler Group LLC CA. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for TG Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 24.53% of TG Therapeutics' floating shares are currently sold short. Is TG Therapeutics' short interest increasing or decreasing? TG Therapeutics saw a decline in short interest in March. As of March 15th, there was short interest totaling 34,190,000 shares, a decline of 1.9% from the previous total of 34,840,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is TG Therapeutics' float size? TG Therapeutics currently has issued a total of 154,420,000 shares. Some of TG Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. TG Therapeutics currently has a public float of 139,360,000 shares. How does TG Therapeutics' short interest compare to its competitors? 24.53% of TG Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to TG Therapeutics: Rhythm Pharmaceuticals, Inc. (15.30%), PTC Therapeutics, Inc. (14.21%), Keros Therapeutics, Inc. (5.34%), Rocket Pharmaceuticals, Inc. (11.31%), Vera Therapeutics, Inc. (16.23%), Corcept Therapeutics Incorporated (22.65%), Galapagos NV (2.24%), Summit Therapeutics Inc. (20.37%), Dyne Therapeutics, Inc. (13.66%), Amphastar Pharmaceuticals, Inc. (10.42%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Cummins Inc. ($8.93 billion), Canadian Natural Resources Limited ($7.79 billion), Super Micro Computer, Inc. ($4.31 billion), T-Mobile US, Inc. ($4.00 billion), General Motors ($3.36 billion), Occidental Petroleum Co. ($3.10 billion), Charter Communications, Inc. ($2.92 billion), Coinbase Global, Inc. ($2.74 billion), Tractor Supply ($2.72 billion), and Moderna, Inc. ($2.31 billion). View all of the most shorted stocks. What does it mean to sell short TG Therapeutics stock? Short selling TGTX is an investing strategy that aims to generate trading profit from TG Therapeutics as its price is falling. TGTX shares are trading up $0.13 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against TG Therapeutics? A short squeeze for TG Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of TGTX, which in turn drives the price of the stock up even further. How often is TG Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including TGTX, twice per month. The most recent reporting period available is March, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Keros Therapeutics Short Interest Rhythm Pharmaceuticals Short Interest Rocket Pharmaceuticals Short Interest Alpine Immune Sciences Short Interest Corcept Therapeutics Short Interest Dyne Therapeutics Short Interest Vera Therapeutics Short Interest Evotec Short Interest Merus Short Interest Galapagos Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:TGTX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics